The Impact of Chemotherapy on Hepatitis B Antibody Titer in Patients with Hematological MalignanciesMünci Yağcı, Elif Suyanı, Merih Kızıl ÇakarGazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey
INTRODUCTION: To investigate the influence of chemotherapy (CT) on HBsAb titer in patients receiving CT due to hematological malignancy.
METHODS: The data of 75 patients who received CT with the diagnosis of various hematological malignancies and who had serum HBsAb levels measured prior to and after the cessation of CT were evaluated retrospectively.
RESULTS: The median age of the patients was 52 years (range: 16-78) with 49 (65%) males and 26 (35%) females. Median HBsAb titer decreased significantly after CT compared to the pre-CT median HBsAb titer [68 (range: 0-1000) vs. 100 (range: 6.2-1000)] (p=0.001). In subgroup analysis, median HBsAb titer decreased significantly after CT in acute leukemia patients [110 (range: 6.2-1000) vs. 67.8 (range: 0-1000)] (p=0.003) and in patients receiving intensive CT [97.2 (range: 6.2-1000) vs. 71 (range: 0-1000)] (p=0.036). The decrease in median HBsAb titer was significant in male patients (p<0.001). HBsAb became negative after CT in 9 patients who were HBcAb-negative and had lower pre-CT HBsAb levels.
DISCUSSION AND CONCLUSION: HBsAb decreased after CT, especially in acute leukemia and male patients, and in patients receiving intensive CT.
Keywords: Hepatitis B, Resolved infection, Hepatitis B surface antibody, Hematological malignancy, Chemotherapy
Hematolojik Maligniteli Hastalarda Kemoterapinin Hepatit B Antikor Titrelerine EtkisiMünci Yağcı, Elif Suyanı, Merih Kızıl ÇakarGazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey
GİRİŞ ve AMAÇ: Bu çalışmada, hematolojik malignite nedeniyle kemoterapi alan hastalarda kemoterapinin Anti HBs antikor titresi üzerine olan etkisinin incelenmesi amaçlanmıştır.
YÖNTEM ve GEREÇLER: Çeşitli hematolojik malignite tanısı ile kemoterapi alan ve hem kemoterapi öncesi hem de kemoterapi tamamlandıktan sonraki AntiHBs antikor titresi mevcut olan toplan 75 hasta retrospektif olarak incelendi.
BULGULAR: Hastaların ortanca yaşı 52 ( 16-78) olup 49 (65%)’u erkek ve 26 (35%)’sı kadın idi. Kemoterapi sonrası ortanca Anti HBs antikor titresinde kemoterapi öncesine göre anlamlı düşme saptandı [68 (range, 0-1000) v.s 100 (range, 6,2-1000)] (p=0.001).
TARTIŞMA ve SONUÇ: Anti HBs antikor titresinde kemoterapi sonrasında azalma görülmüştür ve bu azalma akut lösemi hastalarında, erkek hastalarda ve yoğun kemoterapi alan hastalarda daha belirgin olarak saptanmıştır.
Anahtar Kelimeler: Hepatit B, Geçirilmiş enfeksiyon, Hepatit B yüzey antikoru, Hematolojik malignite, Kemoterapi
Münci Yağcı, Elif Suyanı, Merih Kızıl Çakar. The Impact of Chemotherapy on Hepatitis B Antibody Titer in Patients with Hematological Malignancies. Turk J Hematol. 2015; 32(3): 251-256
Corresponding Author: Münci Yağcı, Türkiye |
|